Genprex Inc (GNPX) Stock Price, Quote & News

Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqor...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 774 4679

Website: www.genprex.com

Address:

3300 Bee Cave Road, Suite 650-227, Austin, United States

SmartOptionsAlert Dec. 27 at 2:44 PM

🔎 $GNPX Options Scan Update (08:44 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai

0 · Reply

RedShanks Dec. 26 at 10:35 PM

$GNPX This should see a big pump soon, keep it on watch!

0 · Reply

OverTheCounter Dec. 26 at 10:16 PM

$GNPX Bull don't deserve this kind of treatment.

0 · Reply

shuffle13 Dec. 26 at 6:31 PM

$GNPX any readouts being waited for?

1 · Reply

StockCaptain7 Dec. 26 at 6:24 PM

$GNPX at this point it really does feel like we’re in the waiting room. They’ve filed what they needed to file, Nasdaq has the info, and now it’s just a case of hearing back. With the deadline sitting at the 31st, any update is likely to land sooner rather than later. Whether people like the stock or not, this is one of those moments where news can drop at any time, and that’s why it stays on the watchlist.

0 · Reply

StockCaptain7 Dec. 26 at 6:22 PM

$GNPX Funny thing with this stock. Everyone says they hate it. Everyone says it’s dead. Everyone says it’s uninvestable. And yet… everyone knows the ticker, everyone has an opinion, and everyone seems to be watching it anyway. You don’t have to like a stock to keep an eye on it. Markets don’t move on feelings, they move on catalysts and reactions. Do with that what you will 😉

0 · Reply

canitin231 Dec. 26 at 2:46 PM

$GNPX waiting for the big announcement

2 · Reply

P_etheris Dec. 26 at 2:37 PM

$GNPX I hate this stock!!! I F-ing hate it🤣🤣🤣

0 · Reply

SmartOptionsAlert Dec. 25 at 10:12 PM

🔎 $GNPX Options Scan Update (16:12 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai

0 · Reply

Tunacanman Dec. 24 at 4:54 PM

$GNPX wait untill end of September beginning of October to buy this. Thank me later.

1 · Reply

Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer

Nov 19, 2025, 7:00 AM EST - 5 weeks ago

Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Nov 18, 2025, 7:00 AM EST - 5 weeks ago

Genprex Announces U.S. Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers

Nov 4, 2025, 7:00 AM EST - 7 weeks ago

Genprex Announces European Patent Office's Intent to Grant a Patent for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer

Oct 28, 2025, 11:19 AM EDT - 2 months ago

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules

Oct 28, 2025, 7:00 AM EDT - 2 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 23, 2025, 8:12 AM EDT - 2 months ago

Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules

Oct 23, 2025, 7:00 AM EDT - 2 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 2, 2025, 8:30 AM EDT - 4 months ago

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Aug 18, 2025, 9:29 AM EDT - 4 months ago

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

Aug 4, 2025, 8:30 AM EDT - 5 months ago

Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Jun 24, 2025, 9:25 AM EDT - 6 months ago

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 23, 2025, 9:00 AM EDT - 6 months ago

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

Jun 3, 2025, 7:00 AM EDT - 7 months ago

Genprex to Participate at BIO 2025 International Convention

May 29, 2025, 7:00 AM EDT - 7 months ago

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

May 28, 2025, 7:00 AM EDT - 7 months ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

May 7, 2025, 7:00 AM EDT - 8 months ago

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

May 6, 2025, 7:00 AM EDT - 8 months ago

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

Apr 30, 2025, 7:30 AM EDT - 8 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Apr 29, 2025, 7:30 AM EDT - 8 months ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Apr 28, 2025, 7:30 AM EDT - 8 months ago

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Apr 24, 2025, 8:15 AM EDT - 8 months ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Apr 22, 2025, 8:15 AM EDT - 8 months ago

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Mar 26, 2025, 8:15 AM EDT - 9 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Mar 25, 2025, 8:15 AM EDT - 9 months ago

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Mar 4, 2025, 8:15 AM EST - 10 months ago

Genprex to Participate at BIO Europe Spring 2025

Feb 19, 2025, 8:15 AM EST - 11 months ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Feb 18, 2025, 8:15 AM EST - 11 months ago

Genprex Provides Update on Diabetes Gene Therapy Program

Feb 13, 2025, 8:15 AM EST - 11 months ago

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Jan 23, 2025, 8:00 AM EST - 1 year ago

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Jan 6, 2025, 9:15 AM EST - 1 year ago

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 9:15 AM EST - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Nov 20, 2024, 9:29 AM EST - 1 year ago

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

Nov 5, 2024, 9:29 AM EST - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Oct 31, 2024, 9:29 AM EDT - 1 year ago

Genprex to Participate in 2024 BIO Europe Conference

Oct 28, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Oct 24, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

Oct 15, 2024, 9:29 AM EDT - 1 year ago

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Oct 10, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 7, 2024, 9:29 AM EDT - 1 year ago

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Sep 23, 2024, 9:29 AM EDT - 1 year ago

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Sep 19, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

Sep 4, 2024, 9:29 AM EDT - 1 year ago

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Aug 15, 2024, 9:30 AM EDT - 1 year ago

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Aug 14, 2024, 9:25 AM EDT - 1 year ago

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

Aug 13, 2024, 8:31 AM EDT - 1 year ago

Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers

Aug 8, 2024, 8:30 AM EDT - 1 year ago

Genprex to Present at the August Sidoti Microcap Conference

Jun 27, 2024, 8:31 AM EDT - 1 year ago

Genprex Issues Stockholder Letter and Provides 2024 Corporate Update

May 30, 2024, 8:31 AM EDT - 1 year ago

Genprex to Present at the 2024 BIO International Convention

May 14, 2024, 8:31 AM EDT - 1 year ago

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

SmartOptionsAlert Dec. 27 at 2:44 PM

🔎 $GNPX Options Scan Update (08:44 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai

0 · Reply

RedShanks Dec. 26 at 10:35 PM

$GNPX This should see a big pump soon, keep it on watch!

0 · Reply

OverTheCounter Dec. 26 at 10:16 PM

$GNPX Bull don't deserve this kind of treatment.

0 · Reply

shuffle13 Dec. 26 at 6:31 PM

$GNPX any readouts being waited for?

1 · Reply

StockCaptain7 Dec. 26 at 6:24 PM

0 · Reply

StockCaptain7 Dec. 26 at 6:22 PM

0 · Reply

canitin231 Dec. 26 at 2:46 PM

$GNPX waiting for the big announcement

2 · Reply

P_etheris Dec. 26 at 2:37 PM

$GNPX I hate this stock!!! I F-ing hate it🤣🤣🤣

0 · Reply

SmartOptionsAlert Dec. 25 at 10:12 PM

🔎 $GNPX Options Scan Update (16:12 CT) No standout unusual options activity right now. Bias: Neutral • Waiting for stronger flow https://smartoptions.ai

0 · Reply

Tunacanman Dec. 24 at 4:54 PM

$GNPX wait untill end of September beginning of October to buy this. Thank me later.

1 · Reply

ACInvestorBlog Dec. 24 at 9:42 AM

$GNPX Delisting risk is low right now thanks to the reverse split and fundraising imho todays sanofi aquistion of $DVAX could fuel shares of small bio names. Tim Moore purchased a lot of shares recently so i think at current levels worth a look. We should get news from NASDAQ this or next week imho

0 · Reply

P_etheris Dec. 24 at 8:29 AM

$GNPX Bloody biotechs… messing up my Xmas gains …🤔🤌😅

0 · Reply

NJS2005 Dec. 24 at 1:48 AM

$GNPX Looks like 3 insider buys were filed tonight

1 · Reply

StockCaptain7 Dec. 23 at 11:15 PM

$GNPX

0 · Reply

OverTheCounter Dec. 23 at 10:56 PM

$GNPX This stock is complete garbage.

0 · Reply

ACInvestorBlog Dec. 23 at 6:44 PM

$GNPX is now trading significantly below cash. Todays Form 8-K " the Company believes it has stockholders’ equity in excess of the Stockholders’ Equity Requirement. " basically Genprex says in the Form 8-K that its stockholders’ equity now exceeds Nasdaq’s minimum listing requirement. Just a reminder: Republican Tim Moore pirchased shares of GNPX in October and November.

0 · Reply

P_etheris Dec. 23 at 4:01 PM

$GNPX Fook this 🤬

0 · Reply

RidingUptrends Dec. 23 at 3:40 PM

If you like getting in them before the massive moves.. Drop @MomentumZeus a FOLLOW below. He's been calling some insane runners lately.. 🚀 Follow trend on $ACHR $QS $GNPX $NVNI now

0 · Reply

JohnTrack Dec. 23 at 3:08 PM

$GNPX checking tone of the flow!

0 · Reply

TwongStocks Dec. 23 at 2:20 PM

$GNPX New SEC filing https://www.sec.gov/ix?doc=/Archives/edgar/data/0001595248/000143774925038601/gnpx20251216_8k.htm Company was given until Dec 31 to show compliance with the minimum equity standard (min $2.5m in stockholder' equity). After the Oct offerings plus money raised through the ATM and Lincoln Park equity line of credit, GNPX believes that they are compliant with the equity requirement. However, they are still waiting for official confirmation from NASDAQ.

0 · Reply

aafetygod Dec. 23 at 2:07 PM

$GNPX We cannot be fully reassured by today's 8-K filing alone. It represents the company's "self-assessment" and is not yet an official confirmation. Violation: Genprex (GNPX) had been warned for non-compliance with the minimum stockholders' equity requirement of $2.5 million under Nasdaq Listing Rule 5550(b). Deadline: The Nasdaq Hearings Panel granted the company an extension until December 31, 2025, to regain compliance with this requirement. Today's Disclosure: Ahead of the deadline, the company reported that it "believes" it has met the criteria by securing the necessary funds. The final decision now rests with the Nasdaq Panel.

0 · Reply

keremoner Dec. 23 at 2:03 PM

$GNPX your old friend here... welcome to the $1 s and before you know, back to the status of being a penny stock (not that it ever stopped being one in reality). Keep on doubling down on your failed delusions that you will somehow hit the bullseye with this one or any other trial stage biotech. And to those who keep posting crap about 'if you missed this run up, come to xyz stock, which undoubtedly will be the next Pfizer', stop doing disservice to gullible investors who have no freaking idea about what they invest in when it comes to trial stage stocks. Hope your eyes open to realities soon. Merry Christmas to all.

1 · Reply

Market Cap	4.31M
Revenue (ttm)	0.00
Net Income (ttm)	-21.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	120,200
Avg Vol	514,823
Day's Range	N/A - N/A
Shares Out	2.32M
Stochastic %K	3%
Beta	-0.77
Analysts	Strong Buy
Price Target	$375.00